IgG2b Enhances Alloantibodies to Stored RBCs

Some patients develop red blood cell (RBC) alloantibodies after transfusion, which can make later transfusions, pregnancies and transplants dangerous. The risk is highest in people with hemolytic anemias such as sickle cell disease. These patients often already have anti-RBC antibodies and usually receive stored blood. This CME activity is based on a mouse study in Transfusion that examines how pre-existing RBC antibodies and changes during blood storage combine to affect immune responses to transfusion. The activity explores the immune mechanisms behind these responses, what they mean for understanding alloimmunization risk in patients who have had many transfusions, and possible targets for reducing that risk in future.

Target Audience

Healthcare Professionals 

Learning Objectives

  • Describe the clinical consequences of RBC alloimmunization, and which patient groups are at highest risk.
  • Explain how pre-existing anti-RBC antibodies of different IgG subclasses affect immune responses to stored RBC transfusions.
  • Describe how blood storage changes (the storage lesion) interact with pre-existing antibodies to increase alloimmunization.
  • Identify the immune pathway involved (FcγRIV on dendritic cells and T cell activation) and why it could be a future target for reducing alloimmunization risk.

Activity Disclosure

No commercial support has been accepted related to the development or publication of this activity.

This activity underwent peer review in line with the standards of editorial integrity and publication ethics. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
Course opens: 
08/12/2025
Course expires: 
08/11/2028
Cost:
$0.00

Article Authors

Jagnarine S, Qiu A, Kyritsis E, Dei Zotti F, and Hudson K

CME Editor

 

Julie Katz Karp MD

Julie Katz Karp MD

Julie Katz Karp MD has nothing to disclose.

 

John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

John Wiley and Sons, Inc. designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within 1 hour. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to three years from initial publication. Additionally, up to 3 attempts and a score of 70% or better is needed to pass the post test and claim CC credit. [ACGME competency/CC category: Medical Knowledge].

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™

Price

Cost:
$0.00
Please login or register to take this course.